Key clinical point: Neoadjuvant chemotherapy (NAC) may increase the odds of a pathological complete response (pCR) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) and BRCA1 mutation vs in those with sporadic BC.
Major finding: The rate of achieving a pCR was significantly higher in BRCA1/2 and BRCA1 mutation carriers vs non-carriers (16% and 38%, respectively, vs 7.8%; P < .001), with BRCA1 mutation carrier vs non-carrier status being associated with higher odds of achieving a pCR (odds ratio 6.31; P = .002).
Study details: Findings are from a retrospective study including 522 patients with HR+/HER2− BC who received NAC, of whom 21 and 38 patients had BRCA1 and BRCA2 mutations, respectively.
Disclosures: This study was partly supported by a US National Institutes of Health/National Cancer Institute Cancer Center Support grant. The authors declared no conflicts of interest.
Source: Myers SP et al. Mutational status is associated with a higher rate of pathologic complete response after neoadjuvant chemotherapy in hormone receptor-positive breast cancer. Ann Surg Oncol. 2023 (Oct 5). doi: 10.1245/s10434-023-14319-0